<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03287245</url>
  </required_header>
  <id_info>
    <org_study_id>NP39761</org_study_id>
    <secondary_id>2017-000861-58</secondary_id>
    <nct_id>NCT03287245</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera</brief_title>
  <official_title>A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, study of idasanutlin monotherapy in participants with
      hydroxyurea (HU)-resistant/intolerant Polycythemia vera (PV).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Anticipated">March 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Response at Week 32 for Ruxolitinib-Naïve Participants With Splenomegaly at Baseline</measure>
    <time_frame>Week 32</time_frame>
    <description>Composite response is defined as hematocrit (Hct) control without phlebotomy and ≥ 35% decrease in spleen size by imaging at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤ 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct of ≥ 45% that was ≥ 3% higher than baseline level or a Hct of &gt; 48% at Week 32.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematocrit (Hct) Control Without Phlebotomy at Week 32 for Ruxolitinib-Naïve Participants Without Splenomegaly at Baseline</measure>
    <time_frame>Week 32</time_frame>
    <description>Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤ 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥ 45% that was ≥ 3% higher than baseline level or a Hct level of &gt; 48% at Week 32.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hct Control Without Phlebotomy at Week 32 for All Ruxolinitib-Naïve Participants (With and Without Splenomegaly)</measure>
    <time_frame>Week 32</time_frame>
    <description>Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤ 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥ 45% that was ≥ 3% higher than baseline level or a Hct level of &gt; 48% at Week 32.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response per Modified European Leukemia Net (ELN) Criteria at Week 32 for Ruxolitinib-Naïve Participants and All Participants Irrespective of Prior Ruxolitinib Exposure</measure>
    <time_frame>Week 32</time_frame>
    <description>Complete hematologic response (CHR) includes all of the following: Hct &lt; 45% without phlebotomy; platelet count ≤ 400 × 10^9/liter (L); white blood cell count ≤ 10 × 10^9/L; normal spleen size on imaging; and no disease-related symptoms. Partial hematologic response (PHR): in participants who do not fulfill the criteria for complete response: Hct &lt; 45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response, Including Percentage of Participants With Durable Response Lasting at Least 12 Weeks</measure>
    <time_frame>Week 32</time_frame>
    <description>Complete hematologic response (CHR) includes all of the following: Hct &lt; 45% without phlebotomy; platelet count ≤ 400 × 10^9/liter (L); white blood cell count ≤ 10 × 10^9/L; normal spleen size on imaging; and no disease-related symptoms. Partial hematologic response (PHR): in participants who do not fulfill the criteria for complete response: Hct &lt; 45% without phlebotomy or response in 3 or more of the other criteria. No response (NR): any response that does not satisfy partial response. Progressive disease (PD): increased bone marrow fibrosis from baseline, and/or transformation to myelofibrosis (MF), myelodysplastic syndrome (MDS) or acute leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Response at Week 32 for Participants With Splenomegaly at Baseline Irrespective of Prior Ruxolitinib Exposure</measure>
    <time_frame>Week 32</time_frame>
    <description>Composite response is defined as hematocrit (Hct) control without phlebotomy and &gt; 35% decrease in spleen size by imaging at Week 32. Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤ 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct of ≥ 45% that was ≥ 3% higher than baseline level or a Hct of &gt; 48% at Week 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hct Control Without Phlebotomy at Week 32 for Participants Without Splenomegaly at Baseline Irrespective of Prior Ruxolitinib Exposure</measure>
    <time_frame>Week 32</time_frame>
    <description>Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤ 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥ 45% that was ≥ 3% higher than baseline level or a Hct level of &gt; 48% at Week 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hct Control Without Phlebotomy at Week 32 for All Participants (With and Without Splenomegaly) Irrespective of Prior Ruxolitinib Exposure</measure>
    <time_frame>Week 32</time_frame>
    <description>Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤ 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥ 45% that was ≥ 3% higher than baseline level or a Hct level of &gt; 48% at Week 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hct Control Without Phlebotomy at Week 32 for All Participants (With and Without Splenomegaly) Who Had Prior Ruxolitinib Exposure</measure>
    <time_frame>Week 32</time_frame>
    <description>Hct control is defined as protocol-specified ineligibility for phlebotomy between Weeks 8 to 32 and ≤ 1 instance of phlebotomy eligibility between first dose and Week 8. Eligibility for phlebotomy is defined as a Hct level ≥ 45% that was ≥ 3% higher than baseline level or a Hct level of &gt; 48% at Week 32.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Abnormal Clinical Laboratory Findings</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug. A SAE is any experience that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The ECOG performance status is a scale used to quantify cancer patients' general well-being and activities of daily life. The scale ranges from 0 to 5, with 0 denoting perfect health and 5 indicating death. The 6 categories are 0=Asymptomatic (Fully active, able to carry on all pre-disease activities without restriction), 1=Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), 2=Symptomatic, &lt; 50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours), 3=Symptomatic, &gt; 50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours), 4=Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair), 5=Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Abnormal Electrocardiogram (ECG) Findings, Vital Signs, and Physical Findings</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Concomitant Medications</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration Observed (Cmax)</measure>
    <time_frame>Day 1, Day 2, Day 5 of Cycle 1</time_frame>
    <description>Cmax is the maximum observed concentration of drug in blood plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Ctrough)</measure>
    <time_frame>Day 1, Day 2, Day 5 of Cycle 1</time_frame>
    <description>Ctrough is the measured concentration of a drug at the end of a dosing interval at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration Observed (tmax)</measure>
    <time_frame>Day 1, Day 2, Day 5 of Cycle 1</time_frame>
    <description>Tmax is the time elapsed from the time of drug administration to maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Day 1, Day 2, Day 5 of Cycle 1</time_frame>
    <description>CL is a measure of the body's elimination of a drug from plasma over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Day 1, Day 2, Day 5 of Cycle 1</time_frame>
    <description>CL/F is a measure of the body's elimination of a drug from plasma over time, after oral administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume or Apparent Volume of Distribution (Vdss/F)</measure>
    <time_frame>Day 1, Day 2, Day 5 of Cycle 1</time_frame>
    <description>Vdss/F is the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Day 1, Day 2, Day 5 of Cycle 1</time_frame>
    <description>AUC (from zero to infinity) represents the total drug exposure over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>Day 1, Day 2, Day 5 of Cycle 1</time_frame>
    <description>t1/2 is defined as the time required for the drug plasma concentration to be reduced to half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Mean Change from Baseline Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)</measure>
    <time_frame>Day 1 of Cycle 1, Cycle 2, Cycle 3, Day 28 of Cycle 5, Week 32, every 3 cycles beyond Week 32, end of study (2 years) or 28 days post last dose</time_frame>
    <description>The MPN-SAF TSS is an assessment form to measure the severity of 9 clinically important symptoms of polycythemia vera. These include: early satiety, abdominal discomfort, inactivity, concentration issues, night sweats, itching, bone pain, fever, and weight loss. The participant provides a severity score for each additional symptom on a scale of 0 (none/absent) to 10 (worst imaginable). A tenth symptom, fatigue, is assessed using the &quot;worst&quot; fatigue item from the Brief Fatigue Inventory (BFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Mean Change from Baseline European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Day 1 of Cycle 1, Cycle 2, Cycle 3, Day 28 of Cycle 5, Week 32, every 3 cycles beyond Week 32, end of study (2 years) or 28 days post last dose</time_frame>
    <description>EORTC QLQ-C30: includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions use a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale [1 'very poor' to 7 'Excellent']). Scores are averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Mean Change from Baseline Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Day 1 of Cycle 2, Cycle 3, Day 28 of Cycle 5, Week 32, every 3 cycles beyond Week 32, end of study (2 years) or 28 days post last dose</time_frame>
    <description>The PGIC is a one-item measure used to assess perceived treatment benefit. Participants will be asked &quot;Since the start of the treatment you've received in this study, your polycythemia vera (PV) symptoms are: 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', and 'very much worse'.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>Idasanutlin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 milligrams (mg), once daily for 5 days, every 28 days, until treatment discontinuation or up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idasanutlin</intervention_name>
    <description>150 milligrams (mg) orally, once daily for 5 days, every 28 days, until treatment discontinuation or up to 2 years.</description>
    <arm_group_label>Idasanutlin</arm_group_label>
    <other_name>RO5503781</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt; 18 years of age

          -  Documentation that the participant has met the revised 2016 World Health Organization
             (WHO) criteria for the diagnosis of polycythemia vera (PV)

          -  Hematocrit at screening and at initiation of idasanutlin &gt; 40%

          -  Phlebotomy-dependent participants with splenomegaly by magnetic resonance imaging
             (MRI) or computerized tomography (CT) imaging (≥ 450 cubic centimeters [cm^3]) or
             without splenomegaly (&lt; 450 cm^3, unpalpable, or prior splenectomy)

          -  Resistance to/intolerance to hydroxyurea according to modified European Leukemia Net
             (ELN) criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Participants must be willing to submit the blood sampling and bone marrow sampling for
             the pharmacokinetic (PK) and pharmacodynamic analyses and exploratory biomarkers

          -  Adequate hepatic and renal function

          -  For women of childbearing potential: agreement to use contraceptive methods that
             result in a failure rate of &lt; 1% per year during the treatment period and for at least
             6 weeks after the last dose of idasanutlin

          -  For men: Agreement to use contraceptive measures, and agreement to refrain from
             donating sperm during the treatment period and for at least 90 days after the last
             dose of idasanutlin

        Exclusion Criteria:

          -  Meets the criteria for post-PV myelofibrosis as defined by the International Working
             Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

          -  Blast phase disease (&gt;20% blasts in the marrow or peripheral blood)

          -  Clinically-significant thrombosis within 3 months of screening

          -  Participants who must receive CYP2C8 inhibitors, substrates and inducers, strong
             CYP3A4 inducers, or OATP1B1/3 substrates while on study. These must be discontinued 7
             days (inhibitors and substrates) or 14 days (inducers) prior to start of study
             medication

          -  Participants previously treated with murine double minute 2 (MDM2) antagonist
             therapies or participants receiving interferon-alpha, anagrelide, or ruxolitinib
             within 28 days or 5 half-lives, or hydroxyurea within 1 day, or participants receiving
             any other cytoreductive or investigational agents within 28 days or 5 half-lives of
             initial dose. Aspirin is permitted per treatment guidelines for PV unless medically
             contraindicated

          -  Participants with evidence of electrolyte imbalance such as hypokalemia, hyperkalemia,
             hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia of Grade &gt; 1
             intensity, as per the National Cancer Institute Common Terminology Criteria for
             Adverse Events (NCI CTCAE), version 4.0, prior to dosing on Cycle 1 Day 1. Treatment
             for correction of electrolyte imbalances is permitted to meet eligibility

          -  Neutrophil count &lt; 1.5 × 10^9/liter (L) prior to dosing on Cycle 1 Day 1

          -  Platelet count ≤ 150 × 10^9/L prior to dosing on Cycle 1 Day 1

          -  Women who are pregnant or breastfeeding

          -  Ongoing serious non-healing wound, ulcer, or bone fracture

          -  History of major organ transplant

          -  Uncontrolled intercurrent illness including, but not limited to hepatitis, concurrent
             malignancy that could affect compliance with the protocol or interpretation of
             results, hepatitis A, B, and C, human immunodeficiency virus (HIV)-positive, ongoing
             or active infection, clinically significant cardiac disease (New York Heart
             Association Class III or IV), symptomatic congestive heart failure, unstable angina
             pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  Participants with active gastrointestinal conditions (Crohn's disease, ulcerative
             colitis, diverticulosis associated colitis, and Behçet's disease)

          -  Clinically significant toxicity (other than alopecia) from prior therapy that has not
             resolved to Grade ≤ 1 (according to the NCI CTCAE, v4.0) prior to Cycle 1 Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID: NP39761 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center; Westwood Cancer Center/BMT Output Clinic</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MSKCC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Cancer Center</name>
      <address>
        <city>Independence</city>
        <state>Ohio</state>
        <zip>44131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center in San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre; Department of Haematology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital; Department of Med Oncology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST PAPA GIOVANNI XXIII; Ematologia</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Circolo E Fondazione Macchi; Ematologia</name>
      <address>
        <city>Varese</city>
        <state>Lombardia</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliero-Universitaria Careggi; CRIMM</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.pioneeringhealthcare.com/p-vera</url>
    <description>Pioneeringhealthcare.com supports an online community of people impacted by Polycythemia Vera (PV, or P Vera), and provides explanations of medical terms and insights about the purpose of Roche's new clinical trial (NP39761) for patients with P Vera.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>September 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>polycythemia vera</keyword>
  <keyword>PV</keyword>
  <keyword>P vera</keyword>
  <keyword>myeloproliferative diseases</keyword>
  <keyword>hematologic diseases</keyword>
  <keyword>myeloproliferative neoplasm</keyword>
  <keyword>MPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

